CPV Parameter Selection and Traceability Matrix

Document type	Matrix
Topic area	Process Validation
Level	Advanced
Updated	September 2026

This is a ready-to-use traceability matrix for a Continued Process Verification program. Its job is narrow and specific: put every monitored parameter, and every parameter deliberately left out, in one table that traces back to the Stage 1 risk assessment, so a reviewer can check the CPV plan’s coverage in a single pass instead of cross-referencing two documents by hand. This matrix is a companion to the CPV plan, not a replacement for it; the plan states the program’s methods and escalation rules, this matrix proves each parameter’s inclusion or exclusion is traceable. Replace every <<FILL: ...>> placeholder with your own specifics. A filled specimen follows.

Document control header

Field	Entry
Document title	CPV Parameter Traceability Matrix for `<<FILL: product / process>>`
Document number	`<<FILL: e.g. CPV-TM-2026-01>>`
Version	`<<FILL>>`
Effective date	`<<FILL>>`
Linked CPV plan	`<<FILL: document number>>`
Linked Stage 1 risk assessment	`<<FILL: document number>>`
Matrix owner	`<<FILL: e.g. Process Owner / Validation>>`

1. Purpose

This matrix traces every parameter monitored under the CPV plan referenced above back to the Stage 1 criticality assessment that identified it, states the monitoring method and control limit basis for each, and records why any parameter the Stage 1 assessment flagged as a CQA or CPP is not separately charted, if that is the case. A monitored parameter with no traceable source, or a known CPP absent from this matrix with no documented reason, is the specific gap this document is built to prevent.

2. Scope

Dimension	Decision
Process / product in scope	`<<FILL>>`
Stage 1 document(s) this matrix traces to	`<<FILL: document number(s) and date>>`
Review cadence for this matrix itself	`<<FILL: e.g. reviewed at every CPV plan revision and at each annual review>>`

3. Parameter traceability

Parameter	Type (CQA / CPP / key process parameter / leading indicator)	Stage 1 source (document, section)	Monitoring method / chart type	Control limit basis	Review frequency	Owner
`<<FILL>>`	`<<FILL>>`	`<<FILL>>`	`<<FILL: I-MR, Xbar-R, c/u/np/p, qualitative trend review, multivariate model>>`	`<<FILL: established control limits from n batches, provisional limits seeded from PPQ, specification used as interim proxy pending sufficient data>>`	`<<FILL: every batch, monthly, quarterly>>`	`<<FILL>>`

Add one row per parameter. Do not compress multiple distinct CQAs or CPPs into one row for brevity; a reviewer checking this matrix against the Stage 1 document needs a one-to-one match.

4. Parameters identified in Stage 1 but not independently charted

Parameter	Stage 1 source	Why it is not separately charted	Where its risk is otherwise covered
`<<FILL>>`	`<<FILL>>`	`<<FILL: e.g. always moves with a parameter already charted above, tested only at a frequency too low to trend meaningfully>>`	`<<FILL: e.g. covered by the correlated parameter's chart, covered under a separate cleaning validation program>>`

Leave this section explicitly empty, stated as “none,” rather than omitting it, if every Stage 1 CQA and CPP is charted above. An inspector comparing this matrix to the Stage 1 assessment is checking for exactly this kind of silent gap.

5. Multivariate monitoring, if applicable

Field	Entry
Is a multivariate model (e.g. Hotelling T-squared, prediction error) in use for any parameter group	`<<FILL: yes/no>>`
If yes, which parameters feed the model	`<<FILL>>`
Training set basis and last retraining date	`<<FILL>>`

6. Revision history

Version	Date	Author	Summary of change
`<<FILL: 1.0>>`	`<<FILL>>`	`<<FILL>>`	Initial issue.

7. Approvals

Role	Name	Signature	Date
Author (Process owner / Validation)	`<<FILL>>`
Reviewer (Statistician or designee)	`<<FILL>>`
Approver (Quality Assurance)	`<<FILL>>`

Filled specimen

Extract for an example allogeneic cell therapy drug substance process. Company and numbers are illustrative.

Parameter	Type	Stage 1 source	Monitoring method / chart type	Control limit basis	Review frequency	Owner
Final cell viability	CQA	Stage 1 Risk Assessment RA-014, Section 6.2	I-MR	Established, 31 commercial batches	Every batch	Process Owner
Fold expansion ratio	CPP-linked leading indicator	RA-014, Section 6.3	I-MR, normalized metric (output / input viable cells)	Established, 31 commercial batches	Every batch	MSAT
Endotoxin	CQA	RA-014, Section 6.2	Qualitative trend review against specification	Interim; fewer than 20 batches with quantifiable results above assay floor	Every batch	QC / Process Owner
Vector copy number	CPP	RA-014, Section 6.4	I-MR	Provisional, seeded from PPQ (n=4) pending commercial accumulation	Every batch	MSAT
Bioreactor dissolved oxygen setpoint deviation count	Key process parameter, leading indicator	RA-014, Section 6.5	c-chart	Established, 31 commercial batches	Every batch	Manufacturing

Section 4, parameters not independently charted:

Parameter	Stage 1 source	Why it is not separately charted	Where its risk is otherwise covered
Media lot identity	RA-014, Section 6.6	Not itself a measured quality attribute; its effect surfaces through fold expansion and final viability, both charted above	Fold expansion and final viability charts; a media-lot change is also logged and cross-checked against any signal on those charts

Section 5: no multivariate model currently in use; fold expansion and final viability are reviewed for co-movement manually each cycle, and a multivariate model is planned once the commercial batch count passes 40.

Common inspection findings this matrix prevents

A known CPP from the Stage 1 risk assessment with no corresponding chart anywhere in the CPV documentation, discovered only when an inspector cross-references the two documents directly.
A parameter charted in the CPV plan with no stated Stage 1 source, so its inclusion looks arbitrary rather than risk-based.
Provisional or interim control limit bases left unstated, so a reviewer cannot tell a mature, established limit from a limit seeded from four PPQ batches.
Parameters correlated with a charted CQA left completely unaddressed, with no statement of where that risk is covered.

How to adapt this matrix

Build this matrix directly from the Stage 1 risk assessment’s CQA and CPP list, not from whatever the historian currently trends; add rows for gaps the current program has not yet closed rather than omitting them.
State the control limit basis honestly in every row: established, provisional and seeded, or specification-as-interim-proxy. A reviewer needs to know which parameters carry mature statistical weight and which do not.
Keep Section 4 current. A parameter that moves from “not separately charted” to “charted” needs a matrix update, not just a CPV plan update.
Revisit this matrix at every CPV plan revision and at the annual review, and reconcile it against the current Stage 1 risk assessment if that document has itself been revised.